Dipeptidyl-Peptidase IV Inhibitors: all 899 studies that test it

Page 8 of 9. Open to participants first (28), then studies with results posted, then the rest; newest registration first within each.

• Study in Healthy Male Subjects Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C] LC15-0444CompletedNCT01603238Phase 1
• Phase III Trial to Evaluate the Efficacy and Safety of LC15-0444 Compared With Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 DiabetesCompletedNCT01602003Phase 3
• Phase 3 Trial to Evaluate the Efficacy and Safety of LC15-0444 in Patients With Type 2 DiabetesCompletedNCT01601990Phase 3
• BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 500mg in Comparison to Each Component Administered AloneCompletedNCT01595880Phase 1
• Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin With or Without Metformin, in Patients With Type 2 Diabetes MellitusCompletedNCT01582230Phase 3
• A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C PatientsTerminatedNCT01567540Phase 1
• Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin MonotherapyStatus unknownNCT01565096Phase 4
• Evaluation of Vildagliptin (Galvus®) as add-on to Insulin in New-onset Type 1 Diabetes MellitusStatus unknownNCT01559025Phase 3
• Saxagliptin and AtherosclerosisCompletedNCT01552018Phase 4
• Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes MellitusStatus unknownNCT01547104Phase 4
• Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)CompletedNCT01541956Phase 4
• Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin AloneCompletedNCT01529541Phase 3
• A Study to Efficacy and Safety of CWP-0403 in Type 2 Diabetes Mellitus PatientsCompletedNCT01529528Phase 3
• Effects of DPP-4 Inhibition on TriglyceridesSuspendedNCT01527747Phase 4
• Study of Combination Therapy With SYR-322CompletedNCT01521962Phase 3
• ACute and Chronic Effects of SaxagliptinCompletedNCT01521312Phase 2
• Vildagliptin Versus Liraglutide - Patient Preference After Receiving Both MedicationsCompletedNCT01518101Phase 4
• MK-0431/ONO-5435 Phase III Clinical Trial-Rapid-acting Insulin Secretagogue Add-on Study in Patients With Type 2 DiabetesCompletedNCT01517321Phase 3
• Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 DiabetesCompletedNCT01497522Phase 3
• Effect of Autonomic Neuropathy on the Efficacy of a DPP-IV Inhibitor (Galvus) TherapyCompletedNCT01452113Phase 2
• Study in Healthy Subjects to Measure Amount of Drug in Blood After Dosing With Different Saxagliptin / Metformin ProducCompletedNCT01441869Phase 1
• A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 DiabeticsCompletedNCT01441232Phase 1
• Long-term Study of SYR-472CompletedNCT01431807Phase 3
• Vildagliptin 50 mg Twice Daily in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With MetforminCompletedNCT01426802Phase 4
• The Swiss Glucose Variability StudyStatus unknownNCT01426737Phase 4
• Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of LC15-0444 and Metformin After Oral Administration in Healthy Male SubjectsCompletedNCT01426399Phase 1
• Pharmacodynamics of Mitiglinide/Sitagliptin Compared to Mitiglinide and SitagliptinCompletedNCT01422590Phase 1
• Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes MellitusCompletedNCT01414920Phase 2
• Vildagliptin Versus Sitagliptin - Differences in Fasting Plasma Glucose Lowering EfficacyCompletedNCT01398592Phase 4
• Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 DiabetesCompletedNCT01357252Phase 3
• Study to Assess the Effect of 24 Weeks of Treatment With Vildagliptin in Patients With Type 2 DiabetesCompletedNCT01356381Phase 4
• Glucose Control in Pre-Diabetic Renal Transplant PatientsCompletedNCT01346254Phase 2
• Effects of Sitagliptin on Type 2 Diabetes Mellitus Patients on Treatment With Metformin and InsulinCompletedNCT01341717Phase 4
• Compare the Effect of DPP-IV Inhibitor or TZD on Glycemic Variability and Oxidative Stress in Patient With 2 DiabetesStatus unknownNCT01339143Phase 4
• Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver DiseasesStatus unknownNCT01337440Phase 4
• Metformin and Sitagliptin in Women With Previous Gestational DiabetesCompletedNCT01336322Phase 2
• Effects of Saxagliptin on Endothelial FunctionCompletedNCT01319357Phase 3
• Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 DiabetesCompletedNCT01309698Phase 4
• BE Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin HCl XR Tablet Relative to a 5 mg Saxagliptin (Onglyza™) Tablet and a 500 mg Metformin HCl XR (Glifage® XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed StatesWithdrawnNCT01305551Phase 1
• Effects of Alogliptin on Pancreatic Beta Cell FunctionStatus unknownNCT01303055Not applicable
• Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe HyperglycemiaCompletedNCT01267448Phase 4
• Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device.CompletedNCT01262586Phase 3
• Sitagliptin for the Treatment of Non-alcoholic Steatohepatitis in Patients With Type 2 DiabetesTerminatedNCT01260246Not applicable
• Sitagliptin in Cystic Fibrosis-Related DiabetesTerminatedNCT01257464Phase 2
• Safety and Efficacy of Galvus in Elderly Type 2 Diabetes PatientsCompletedNCT01257451Phase 3
• A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic PatientsCompletedNCT01242228Phase 3
• Phase 4 Study in the Elderly Patients With T2DMCompletedNCT01238978Phase 4
• Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes MellitusCompletedNCT01235819Phase 4
• Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus GlimepirideCompletedNCT01233622Phase 3
• Efficacy and Safety of Vildagliptin as add-on Therapy to Insulin in Patients With Type 2 Diabetes MellitusCompletedNCT01224366Phase 3
• Vildagliptin and the Glucagon Response to Hypoglycemia in Insulin-Treated Patients With Type 2 DiabetesCompletedNCT01219400Phase 4
• Investigation of a Switch From Insulin Therapy to a Metformin & Saxagliptin Combination in Patients With Type 2 Diabetes MellitusStatus unknownNCT01206647Phase 4
• Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)CompletedNCT01196546Phase 4
• Glycemic Holter Study (Continuous Glucose Monitoring) -CompletedNCT01193296Phase 4
• A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin TherapyCompletedNCT01169090Phase 2
• Protective Effects of Sitagliptin on β Cell Function in Patients With Adult-onset Latent Autoimmune Diabetes (LADA)CompletedNCT01159847Phase 1/2
• Long-term Safety Study of Vildagliptin in Patients With Type 2 DiabetesCompletedNCT01159249Phase 3
• Vildagliptin and the Glucagon Response to Hypoglycemia in Type 1 DiabetesCompletedNCT01147276Phase 4
• Treatment of Latent Autoimmune Diabetes of the AdultCompletedNCT01140438Not applicable
• A Multicenter, Open Label, Single Dose Study to Evaluate the Effect of Renal Insufficiency on the Pharmacokinetics of SK 0403CompletedNCT01131091Phase 1
• The Vascular Effects of Vildagliptin in Insulin Resistant IndividualsCompletedNCT01122641Phase 3
• A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Sitagliptin When Given Together to Healthy SubjectsCompletedNCT01104532Phase 1
• Long-term Extension Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes MellitusTerminatedNCT01101945Phase 2
• Sitagliptin Versus Insulin Dose Increase in Type 2 Diabetes on Insulin TreatmentCompletedNCT01100125Phase 4
• Effect of Vildagliptin in Type 2 Diabetes Treated With Sulphonylurea and MetforminCompletedNCT01099137Phase 4
• Vascular Effects of Sitagliptin in Diabetes MellitusStatus unknownNCT01096277Phase 4
• Investigate the Effect of AZD1656 on the Pharmacokinetics of Sitagliptin in Patients With Type 2 Diabetes MellitusCompletedNCT01095991Phase 1
• Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone AloneTerminatedNCT01089790Phase 3
• Role of Vitagliptin and Vitamin D in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)Status unknownNCT01083992Not applicable
• Role of Interleukin-6 in ExerciseCompletedNCT01073826Not applicable
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses of JNJ-38431055, Sitagliptin, and Co-administration of JNJ-38431055 and SitagliptinCompletedNCT01054118Phase 1
• Sitagliptin in Prevention of Type 2 Diabetes MellitusWithdrawnNCT01038648Phase 3
• PINGUIN (Postpartum Intervention in Women With Gestational Diabetes Using Insulin)Status unknownNCT01018602Phase 2
• Pharmacokinetic Drug Interaction Between LC15-0444 and Pioglitazone After Oral Administration in Healthy Male SubjectsCompletedNCT01001013Phase 1
• Vildagliptin and Endothelium-dependent VasodilatationCompletedNCT01000688Phase 3
• Safety and Efficacy Study of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of MetforminTerminatedNCT00998686Phase 3
• Vildagliptin in New Onset Diabetes After TransplantationCompletedNCT00980356Phase 2
• Assessing Glucose Effects of Sitagliptin (Januvia) in Adult Patients With Type 1 DiabetesCompletedNCT00978796Phase 4
• Galvus on Met Phase 4 Study : Study to Evaluate the Efficacy and Safety of Early Combination of Vildagliptin and Metformin in Patients With Type 2 Diabetes MellitusCompletedNCT00975065Phase 4
• A Study of the Effects of Sitagliptin (MK0431) and Metformin on Incretin Hormone Concentrations (0431-050)(COMPLETED)CompletedNCT00975052Phase 1
• Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With PioglitazoneTerminatedNCT00970424Phase 3
• Predictive Parameters for Efficacy of Sitagliptin and Metformin CombinationCompletedNCT00969566Phase 4
• Effect of Sitagliptin on Endothelial Progenitor CellsCompletedNCT00968006Phase 4
• Effect of Sitagliptin in Impaired Glucose ToleranceStatus unknownNCT00961363Phase 2
• A Study to Characterize the Pharmacokinetics/Pharmacodynamics and Effect of Food of DA-1229 in Healthy Male SubjectsStatus unknownNCT00961025Phase 1
• Clinical Trial to Investigate the Pharmacokinetics/Pharmacodynamics of SitagliptinCompletedNCT00960453Phase 1
• Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal ImpairmentTerminatedNCT00958269Phase 3
• The Effects of LAF237 on Gastric Function in Type 2 DiabetesCompletedNCT00952991Phase 3
• Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Glimepiride With or Without MetforminTerminatedNCT00947557Phase 3
• Effect of Sitagliptin on Postprandial Lipoprotein MetabolismTerminatedNCT00939939Phase 4
• Functional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus (FINNjA-DM).WithdrawnNCT00936234Phase 2/3
• Pharmacokinetics and Pharmacodynamics Study of Saxagliptin in Healthy SubjectsCompletedNCT00935467Phase 1
• Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart FailureCompletedNCT00894868Phase 4
• "Effect of Dipeptidyl Peptidase IV After Diets in näive Type 2 Diabetic Patients"CompletedNCT00881543Not applicable
• Long-term Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes MellitusTerminatedNCT00865592Phase 3
• Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 DiabetesCompletedNCT00860288Phase 2/3
• A Phase 2 Study of OPC-262 in Patients With Type 2 DiabetesCompletedNCT00857558Phase 2
• MK-0431/ONO-5435 Phase III Clinical Trial - Insulin Add-on Study for Patients With Type 2 Diabetes MellitusCompletedNCT00854035Phase 3
• Effect of Sitagliptin on Graft Function Following Islet TransplantationTerminatedNCT00853944Phase 3
• Safety and Efficacy Study of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus on a Background Medication of MetforminTerminatedNCT00850239Phase 3

← Dipeptidyl-Peptidase IV Inhibitors overview